Oruka Therapeutics (NASDAQ:ORKA) Reaches New 1-Year High – Time to Buy?

by · The Cerbat Gem

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) shares reached a new 52-week high on Monday . The company traded as high as $30.83 and last traded at $30.1030, with a volume of 54878 shares traded. The stock had previously closed at $29.29.

Wall Street Analysts Forecast Growth

ORKA has been the subject of a number of recent analyst reports. Barclays started coverage on Oruka Therapeutics in a research note on Monday, October 13th. They issued an “overweight” rating and a $48.00 price objective for the company. BTIG Research upped their price target on Oruka Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Guggenheim began coverage on shares of Oruka Therapeutics in a research report on Monday, October 27th. They set a “buy” rating and a $60.00 price objective on the stock. Wedbush reissued an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 12th. Finally, HC Wainwright cut their target price on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.14.

Get Our Latest Stock Analysis on ORKA

Oruka Therapeutics Stock Up 2.2%

The stock has a market cap of $1.48 billion, a P/E ratio of -10.86 and a beta of -0.30. The business has a 50 day moving average price of $24.43 and a 200 day moving average price of $17.21.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.01. On average, research analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ORKA. Jefferies Financial Group Inc. grew its position in Oruka Therapeutics by 15.7% during the 1st quarter. Jefferies Financial Group Inc. now owns 405,029 shares of the company’s stock worth $4,156,000 after purchasing an additional 55,000 shares during the last quarter. Candriam S.C.A. acquired a new stake in shares of Oruka Therapeutics during the first quarter worth $1,197,000. AlphaQuest LLC purchased a new stake in shares of Oruka Therapeutics during the first quarter valued at $168,000. Affinity Asset Advisors LLC increased its position in shares of Oruka Therapeutics by 47.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company’s stock valued at $5,595,000 after acquiring an additional 176,664 shares during the period. Finally, OMERS ADMINISTRATION Corp increased its position in shares of Oruka Therapeutics by 126.8% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 44,900 shares of the company’s stock valued at $461,000 after acquiring an additional 25,100 shares during the period. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Further Reading